@article{eb433f1e5e084388a5a5b4edc8a4d642,
title = "B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL)",
abstract = "This randomized, multicenter study evaluates the addition of bortezomib (13 mg/m2) to IGEV (B-IGEV) in patients with relapsed/refractory Hodgkin Lymphoma (HL). Patients received either four courses of IGEV alone (n = 40) or B-IGEV (n = 40). The primary endpoint was the complete response (CR) proportion, evaluated by FDG-PET, after induction chemotherapy. CR proportion was 39% with B-IGEV and 53% with IGEV. PFS and OS were similar between the two groups (two-year PFS: 58% vs 56%; two-year OS: 93% vs 81%). The PET-negative status after treatment was the only variable favorably influencing both PFS (two-year PFS: 77% vs 40%; p = 0.002) and OS (two-year OS: 100% vs 76%; p < 0.001). Toxicity was overall similar with the two regimens. The addition of bortezomib to IGEV does not improve response in relapsed/refractory HL patients. However, its favorable therapeutic and safety profile, and the prognostic role of pre-transplant PET negativity in patients receiving IGEV-based regimens are confirmed. {\textcopyright} 2016 Informa UK Limited, trading as Taylor & Francis Group.",
keywords = "Chemotherapeutic approaches, clinical results, lymphoma and Hodgkin lymphoma",
author = "M. Balzarotti and Ercole Brusamolino and E. Angelucci and A.M. Carella and U. Vitolo and E. Russo and A. Congiu and M. Gotti and Stefania Massidda and B. Botto and Giorgia Annechini and M. Spina and A. Re and Zilioli, {Vittorio Ruggero} and F. Merli and F. Salvi and Caterina Stelitano and M. Bonfichi and M. Rodari and Roberta Murru and Massimo Magagnoli and A. Anastasia and R. Mazza and L. Giordano and A. Santoro",
note = "Export Date: 16 March 2017 CODEN: LELYE Correspondence Address: Santoro, A.; Humanitas Cancer CenterItaly; email: armando.santoro@cancercenter.humanitas.it References: Linch, D.C., Winfield, D., Goldstone, A.H., Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial (1993) Lancet, 341, pp. 1051-1054; Schmitz, N., Pfistner, B., Sextro, M., Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial (2002) Lancet, 359, pp. 2065-2071; Rancea, M., von Tresckow, B., Monsef, I., High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed or refractory Hodgkin lymphoma: a systematic review with meta-analysis (2014) Crit Rev Oncol Hematol, 92, pp. 1-10; Spaepen, K., Stroobants, S., Dupont, P., Prognostic value of pretransplantation positron emission tomography using fluorite 18-fluorodexygluocse in patients with aggressive lymphoma treated with high-dose chemotherapy and stem–cell transplantation (2003) Blood, 102, pp. 53-59; Filmont, J.E., Czernin, J., Yap, C., Value of F-18 fluorodexyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior and after autologous stem-cell transplantation (2006) Chest, 124, pp. 608-613; Moskowitz, C.H., Matasar, M.J., Zelenetz, A.D., Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma (2012) Blood, 119, pp. 1665-1670; Mazza, R., Luminari, S., Magagnoli, M., Pretransplatation PET as major prognostic discriminant in IGEV (ifosfamide, gemcitabine, vinorelbine and prednisone) treated patients with relapsed/refractory Hodgkin{\textquoteright}s lymphoma (HL) (2009) Blood, 114, p. 3707; Velasquez, W.S., Cabanillas, F., Salvador, P., Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP) (1988) Blood, 71, pp. 117-122; Velasquez, W.S., McLaughlin, P., Tucker, S., ESHAP – an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study (1994) J Clin Oncol, 12, pp. 1169-1176; Martin, A., Fernandez-Jimenez, M.C., Caballero, M.D., Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease (2001) Br J Haematol, 113, pp. 161-171; Moskowitz, C.H., Nimer, S.D., Zelenetz, A.D., A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model (2001) Blood, 97, pp. 616-623; Moskowitz, C.H., Kewalramani, T., Nimer, S.D., Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease (2004) Br J Haematol, 124, pp. 645-652; Santoro, A., Magagnoli, M., Spina, M., Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma (2007) Haematologica, 92, pp. 35-41; O'Connor, O.A., Moskowitz, C., Portlock, C., Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial (2009) Br J Haematol, 145, pp. 34-39; O'Connor, O.A., Wright, J., Moskowitz, C., Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma (2005) J Clin Oncol, 23, pp. 676-684; Pajonk, F., Pajonk, P., MvBride, W.H., Apoptosis and radiosensitization of Hodgkin cells by proteasome inhibition (2000) Int J Radiat Oncol Biol Phys, 47, pp. 1025-1032; Fahy, B.N., Schlieman, M.G., Virudachalam, S., Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer (2003) J Surg Res, 113, pp. 88-95; Kamat, A.M., Karashima, T., Davis, D.W., Proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo (2004) Mol Cancer Ther, 3, pp. 279-290; Rakumar, V.S., multiple myeloma: update on diagnosis, risk stratification, and management (2014) Am J Hematol, 89, pp. 999-1009; Bommakanti, S.V., Dudek, A., Phase 1 trial of gemcitabine with bortezomib in elderly patients with advanced solid tumors (2001) Am J Clin Oncol, 34, pp. 597-602; Cheson, B.D., Pfistner, B., Juweid, M.E., Revised response criteria for malignant lymphoma (2007) J Clin Oncol, 25, pp. 579-586; Younes, A., Pro, B., Fayad, L., Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma (2006) Blood, 107, pp. 1731-1732; Blum, K.A., Johnson, J.L., Niedzwiecki, D., Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206 (2007) Leuk Lymphoma, 48, pp. 1313-1319; Mendler, J.H., Kelly, J., Voci, S., Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma (2008) Ann Oncol, 19, pp. 1759-1764; Trelle, S., Sezer, O., Naumann, R., Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT00148018) (2007) Haematologica, 92, pp. 68-69; Fanale, M., Fayad, L., Pro, B., Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma (2011) Br J Haematol, 154, pp. 284-286; Karuturi, M., Younes, A., Fayad, L., ICE (Ifosfamide, Carboplatin, Etoposide) with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trial (2015) Leuk Lymph, 25, pp. 1-8; Anastasia, A., Carlo-Stella, C., Corradini, P., Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi (2014) Br J Haematol, 166, pp. 140-142; Younes, A., Gopal, A.K., Smith, S.E., Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma (2012) J Clin Oncol, 30, pp. 2183-2189; Ansell, S.M., Lesokhin, A.M., Borrello, I., PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma (2015) N Engl J Med, 372, pp. 311-319",
year = "2016",
doi = "10.3109/10428194.2016.1140161",
language = "English",
volume = "57",
pages = "2375--2381",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "10",
}